The oral therapy filgotinib could be a more effective treatment for patients with active ankylosing spondylitis who fail treatment with NSAIDs, according to the results of a study presented at the Clinical Congress of Rheumatology West in San Diego last month.
In a study presented at the Clinical Congress of Rheumatology West held in San Diego last month, researchers led by Brian LaMoreaux, M.D., report that gout was found to be a “a common comorbidity in renal transplant patients.”
Long-term remission in rheumatoid arthritis is rare, but achieving rheumatoid arthritis remission even once can improve function and quality of life, researchers report.
In the September issue of The Lancet Rheumatology, Drs. Janet Pope and Peter C. Taylor review three historical game changers in rheumatoid arthritis treatment.
Sjögren’s syndrome secondary to systemic lupus erythematosus (SLE) rises in frequency with age, affects around one-quarter of all people with systemic lupus, and, despite less internal organ involvement than in systemic lupus without Sjögren’s syndrome, is marked by a systemic inflammatory state with high levels of pro-inflammatory cytokines, say researchers writing in The Journal of Rheumatology this month.
Parenteral methotrexate therapy is more successful than oral methotrexate in achieving optimal disease activity control in rheumatoid arthritis, with no increased adverse effects, say researchers writing in PLoS One this month.
How drug classes such as biologics have given dermatologists confidence in clearing patients' skin.
A 51-year-old woman visits her primary care doctor to address a rash, pruritus, myalgias and muscle weakness. The rash was an erythematous blanching patch spread across her chest in a V shape. She had also noticed that her fingernail folds were red and swollen. What's your diagnosis?
In a new randomized study, investigators compare 2 hip surgeries for elderly patients with a displaced femoral neck fracture.
Fluorescence optical imaging, which enables visualization of inflammation in the hands in rheumatic joint diseases, correlates with ultrasound as a validated and well-established imaging technique in daily rheumatological practice, say researchers writing in Arthritis Research & Therapy this month.
A study presented at CCR West found that tocilizumab displayed better biologic persistence compared with other biologics in patients with rheumatoid arthritis who previously received 1 or more other biologics.
Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.
An international physician group writing in the British journal Annals of the Rheumatic Diseases, has updated recommended parameters that constitute lesions in the sacroiliac joints of patients with spondyloarthritis. The definitions of capsulitis, enthesitis, fat lesion and erosion were revised and new definitions were developed for joint space enhancement, joint space fluid, fat metaplasia in an erosion cavity, ankylosis and bone bud.
Previously, smoking was the sole known modifiable predictor of spinal structural damage, but now alcohol consumption has been shown to be associated with the progression of spinal structural damage in axial spondyloarthritis―specifically by increasing the odds of syndesmophyte progression over two years.
Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.
The incidence of retinopathy among systemic lupus erythematosus (SLE) patents treated with hydroxychloroquine increased with longer treatment duration, but could be predicted by monitoring blood levels of the drug, say researchers writing in Arthritis & Rheumatology this month.
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.
A post hoc analysis of the OPAL Beyond and OPAL Broaden studies found tofacitinib improved skin-related symptoms and health-related quality of life in psoriatic arthritis patients with an inadequate response to csDMARDs or TNFi treatment.
Only 60 percent of patients with rheumatic disease are treated by a rheumatologist, 90 percent have health insurance, but 60 percent struggle to pay for healthcare expenses, survey shows.
A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.
A study examining a gene expression classifier from Scipher Medicine called PrismRA found the system could be used to identify at least half of the non-responders with at least 90% accuracy.
A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.
Theresa Lawrence Ford, MD, CEO and medical director of North Georgia Rheumatology Group and board member of the Association of Women in Rheumatology, gives her opinion on the current state of burnout among rheumatologists.
Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.
AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.
A new study from CCR West compared the JAK inhibitor therapy to competitors across a clinical trial program involving 5 pivotal phase 3 studies.
Maria Greenwald, MD, rheumatologist, discusses what she sees as a glaring issue in medicine—the lack of knowledge among many physicians as to how much treatments will cost and how to mitigate the impact of those costs.
A study from CCR West 2019 has found that tofacitinib can cut the time to clinically significant pain improvement in psoriatic arthritis patients by nearly half the time when compared to placebo therapy.
The indication for the add-on monoclonal antibody makes it the first approved therapy for children with the rare vasculitis conditions.
